Annovis is also seeking fresh capital while working to advance trials for both Alzheimer's and Parkinson's disease drugs.

A once-a-day pill that helps slow down the course of Alzheimer’s disease is a step closer to becoming a reality in a major ...

There's still so much we don't know about Alzheimer's disease, but the link between poor sleep and worsening disease is one ...

Alzheimer’s disease has long resisted simple solutions, but a new line of research suggests an unexpected pairing could help keep the condition at bay: a marijuana-derived compound working alongside a ...

New research suggests THC’s cognitive drawbacks may be mitigated when combined with a targeted anti-inflammatory drug. Cannabis research has highlighted a scientific paradox. Its best-known ...

Anavex (AVXL) blarcamesine faces uncertain FDA path in early Alzheimer’s; Phase 3 may be needed. Read here a detailed ...

From Science.org. "T3D Therapeutics alleges that contract researchers delivered “medically impossible” results on its candidate drug. In 2023, the drug ...

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

In recent years, research into cannabis and its main psychoactive ingredient, Δ⁹-tetrahydrocannabinol (THC), has unearthed ...

In A Nutshell A mouse study found that low-dose THC combined with celecoxib protected memory and reduced brain damage linked to Alzheimer’s. THC alone reduced toxic proteins but also increased ...

Actinogen Medical soon should find out whether its pivotal Xanamia Alzheimer's trial is futile, or hitting the right notes. .

In recent years, research into cannabis and its main psychoactive ingredient, Δ⁹-tetrahydrocannabinol (THC), has unearthed ...